Search Results

You are looking at 31 - 40 of 178 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Harold J. Burstein

end-of-the-year clinics. The results of the ATLAS study were presented at San Antonio. This study addressed the question of extended course tamoxifen treatment beyond 5 years. The data suggest that longer durations of endocrine therapy with tamoxifen

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead

.57–0.94; P =.01). 32 In a multivariate analysis that took into account factors associated with lower IBTR, including grade, ER-positive status, use of adjuvant tamoxifen, margin status, and age, the benefit of RT boost still remained statistically

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead, and Rashmi Kumar

(AI; with ovarian suppression for premenopausal women) or tamoxifen. The preferred endocrine therapy option for postmenopausal women is an AI. HER2-Targeted Therapy: For patients with HER2-positive breast cancer who are candidates for preoperative

Full access

David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman

Castiglione-Gertsch M . Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group trial VII . J Clin Oncol 2000 ; 18 : 1412 – 1422

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars

randomized to undergo lumpectomy with whole breast radiation or lumpectomy alone, both with tamoxifen for 5 years. Locoregional recurrence rates were 1% in the lumpectomy, radiation, and tamoxifen arm, and 4% in the lumpectomy plus tamoxifen arm. No

Full access

Christopher P. Chung, Carolyn Behrendt, Louise Wong, Sarah Flores, and Joanne E. Mortimer

of treatment and not a preexisting problem or from another cause. The National Surgical Adjuvant Breast and Bowel Project (NSABP) developed the Symptom Measurement tool to assess the toxicity of chemopreventive tamoxifen in women enrolled in

Full access

Lee S. Schwartzberg

impactful way we can use these tests,” Dr. Schwartzberg remarked. In NSABP B-14, the benefit of tamoxifen (vs placebo) in patients with ER-positive cancer was seen in the low and intermediate RS groups, but not the high RS group. Discrimination by RS

Full access

Benjamin O. Anderson, Kristine E. Calhoun, and Eric L. Rosen

R . Prognostic significance of benign proliferative breast disease . Cancer 1993 ; 71 : 3896 – 3907 . 15. Fisher B Costantino JP Wickerham DL . Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast

Full access

D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt, and Antonio C. Wolff

comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 . J Clin Oncol 2007 ; 25 : 3846 – 3852 . 12 Badve SS Baehner FL Gray RP . Estrogen- and progesterone-receptor status in ECOG 2197: comparison

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

aged ≥70 years at diagnosis with clinical stage I, node-negative, ER-positive breast cancer with negative margins who were to receive adjuvant tamoxifen randomized patients to receive lumpectomy with WBRT or lumpectomy alone. With a median follow up of